Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, Yang X, Yang C, Xue S, Qiu H, Miao M, Chen S, Jin Z, Fu C, Li C, Sun A, Han Y, Wang Y, Yu L, Wu D, Cui Q, Tang X.
Liu S, et al.
Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5.
Blood Cancer J. 2023.
PMID: 37095120
Free PMC article.